SIETES :: 92718 citas

Resultados de la búsqueda por TDAH REFINAR BÚSQUEDA

1.

Cortese S. Psychosis during attention deficit–hyperactivity disorder treatment with stimulants. N Engl J Med 2019;380:21 de marzo. [Ref.ID 103068]

2.

Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med 2019;380:21 de marzo. [Ref.ID 103067]

3.

Christensen J, Pedersen LH, Sun Y, Dreier JW, Brikell I, Dalsqaard S. Association of prenatal exposure to valproate and other antiepileptic drugs with risk for attention-deficit/hyperactivity disorder in offspring. JAMA Network Open 2019;2:4 de enero. [Ref.ID 103010]

4.

Ray WA, Stein CM, Murray KT, Fuchs DC, Patrick SW, Daugherty J, Hall K, Cooper WO. Association of antipsychotic treatment with risk of unexpected death among children and youths. JAMA Psychiatry 2018:12 de diciembre. [Ref.ID 102895]

5.

Layton TJ, Barnett ML, Hicks TR, Jena AB. Attention deficit-hyperactivity disorder and month of school enrollment. N Engl J Med 2018;379:29 de noviembre. [Ref.ID 102876]

6.

Hales CM, Kit BK, Gu Q, Ogden CL. Trends in prescription medication use among children and adolescents—United States, 1999-2014. JAMA 2018;319:15 de mayo. [Ref.ID 102778]

7.

Angus-Leppan H, Liu RSN. Weighing the risks of valproate in women who could become pregnant. BMJ 2018;361:18 de abril. [Ref.ID 102682]

8.

Kioumourtzoglou M-A, Coull BA, O’Reilly EJ, Ascherio A, Weisskopf MG. Association of exposure to diethylstilbestrol during pregnancy with multigenerational neurodevelopmental deficits. JAMA Pediatrics 2018;172:670-7. [Ref.ID 102638]

9.

Huybrechts KF, Bröms G, Christensen LB, Einarsdóttir K, Engeland A, Furu K, Gissler M, Hernández-Díaz S, Karlsson P, Karlstad Ø, Kieler H, Lahesmaa-Korpinen AM, Mogun H, Nørgaard M, Reutfors J, Sørensen HT, Zoega H, Bateman BT. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the international pregnancy safety study consortium. JAMA Psychiatry 2017:13 de diciembre. [Ref.ID 102188]

10.

Anónimo. Guanfacine et déficit de l'attention avec hyperactivité. Prescrire 2017;37:329-32. [Ref.ID 101647]

11.

Man KKC, Chan EW, Ip P, Coghill D, Simonoff E, Chan PKL, Lau WCY, Schuemie MJ, Sturkenboom MCJM, Wong ICK. Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study. BMJ 2017;357:j2350. [Ref.ID 101616]

12.

Chanq Z, Quinn PD, Hur K, Gibbons RD, Sjolander A, Larsson H, D'Onofrio BM. Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry 2017;74:597-603. [Ref.ID 101569]

13.

Larkin I, Ang D, Steinhart J, Chao M, Patterson M, Sah S, Wu T, Schoen-baum M, Hutchins D, Brennan T, Loewen-stein G. Association between academic medical center pharmaceutical detailing policies and physician prescribing. JAMA 2017;317:1785-95. [Ref.ID 101559]

14.

Anónimo. FDA places hold on experimental ADHD drug. DIA Daily 2016:3. [Ref.ID 100765]

15.

Stergiakouli E, Thapar A, Smith GD. Association of acetaminophen use during pregnancy with behavioral problems in childhood. Evidence against confounding. JAMA Intern Med 2016:15 de agosto. [Ref.ID 100580]

16.

Hoshen MB, Benis A, Keyes KM, Zoëga H. Stimulant use for ADHD and relative age in class among children in Israel. Pharmacoepidemiol Drug Saf 2016;25:652-60. [Ref.ID 100395]

17.

Jackson JW. The cardiovascular safety of methylphenidate. BMJ 2016;353:i2874. [Ref.ID 100356]

18.

19.

Wong J, Motulsky A, Eguale T, Buckeridge DL, Abrahamowicz M, Tamblyn R. Treatment indications for antidepressants prescribed in primary care in Quebec, Canada, 2006-2015. JAMA 2016;315:2230-2. [Ref.ID 100316]

20.

Anónimo. Guanfacine for ADHD in children and adolescents. Drug Ther Bull 2016;54:56-60. [Ref.ID 100276]